Wassil Jim sold $121K of PCVX
Wassil Jim (CHIEF OPERATING OFFICER) sold 2,250 shares of Vaxcyte, Inc. (PCVX) at an average of $53.86 ($53.50–$54.09, $0.12M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new information is the reported insider sale size, timing (2026-08-03), and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider sale for sentiment monitoring, but there is no fundamental update to drive a decisive re-pricing.
What to watch
The disclosure does not include any new company-specific catalyst (trial, approval, guidance, or contract), so traders should avoid extrapolating it into fundamentals.
Background
The article is a SEC Form 4 insider transaction report for Vaxcyte, Inc. (PCVX).
Ticker impact
Vaxcyte COO Wassil Jim sold about 2,250 shares in open-market transactions under a 10b5-1 plan, totaling $121,194.84.
Low likelihood of a sustained price move; any reaction is likely limited and short-lived.
The filing is a routine Form 4 open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying guidance, deal, or operational change disclosed.
Market effects
Minimal. Insider selling in a single biotech name under 10b5-1 does not materially reset sector expectations.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect liquidity or diversification rather than bearish expectations.
Key entities
- issuerVaxcyte, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderWassil Jim
Chief Operating Officer who sold shares in open-market transactions under a 10b5-1 plan.
